Autolus Therapeutics gets FDA RMAT designation for obe-cel in lupus
Autolus Therapeutics says the FDA granted RMAT designation to obe-cel for systemic lupus erythematosus and lupus nephritis.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.